512 related articles for article (PubMed ID: 15833866)
1. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
3. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
4. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
6. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Huang SM; Li J; Armstrong EA; Harari PM
Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
[TBL] [Abstract][Full Text] [Related]
7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
8. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
9. Modulation of radiation response by histone deacetylase inhibition.
Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
[TBL] [Abstract][Full Text] [Related]
10. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
12. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
[TBL] [Abstract][Full Text] [Related]
13. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
15. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
18. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H
Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
